{"schemaVersion":"WPF-PUBLIC-UPDATES-1.0","generatedAt":"2026-09-18T15:03:56.528Z","governance":"Only published governed records are included.","counts":{"evidence":50,"regulatory":25,"corrections":0},"evidence":[{"id":"e296262a3815c3bbcad086b0dc87cd4e","title":"Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials.","updatedAt":"2026-09-11T09:05:08.760Z","publicationYear":2019,"evidenceTier":"observational","doi":"10.1007/s00134-019-05620-2","pubmedId":"31062052","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"2f748d42b788b3ef04182c86c85d9618","title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors.","updatedAt":"2026-09-11T09:02:31.846Z","publicationYear":2014,"evidenceTier":"phase_3","doi":"10.1056/nejmoa1316158","pubmedId":"25014687","peptide":{"slug":"lanreotide","commonName":"Lanreotide"}},{"id":"1863a9da4b512a379d350a3c0f2ce813","title":"Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation.","updatedAt":"2026-09-10T09:04:43.262Z","publicationYear":2025,"evidenceTier":"phase_1_2","doi":"10.1097/pcc.0000000000003642","pubmedId":"39585174","peptide":{"slug":"bivalirudin","commonName":"Bivalirudin"}},{"id":"37424f5504ef5561978aa7df43271e86","title":"Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.","updatedAt":"2026-09-10T09:04:19.824Z","publicationYear":2023,"evidenceTier":"observational","doi":"10.7326/m22-0684","pubmedId":"36592455","peptide":{"slug":"abaloparatide","commonName":"Abaloparatide"}},{"id":"6b3269d49015302276b7e0e58df0e594","title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.","updatedAt":"2026-09-10T09:04:02.368Z","publicationYear":2023,"evidenceTier":"observational","doi":"10.1136/bmj-2021-068033","pubmedId":"37130601","peptide":{"slug":"abaloparatide","commonName":"Abaloparatide"}},{"id":"de5c012da91a63ebf43c0251d5bc63ce","title":"Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.","updatedAt":"2026-09-10T09:03:43.500Z","publicationYear":2015,"evidenceTier":"phase_1_2","doi":"10.1016/s0140-6736(15)61120-5","pubmedId":"26144908","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"91fe23f577af8cc28eca5e8616e2d381","title":"Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.","updatedAt":"2026-09-10T09:03:25.533Z","publicationYear":2023,"evidenceTier":"observational","doi":"10.7326/m22-0684","pubmedId":"36592455","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"ee4b0f2316f1dfa807dd90778ef89d26","title":"Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.","updatedAt":"2026-09-10T09:02:50.393Z","publicationYear":2023,"evidenceTier":"phase_3","doi":"10.1056/nejmoa2303974","pubmedId":"37851874","peptide":{"slug":"leuprolide","commonName":"Leuprolide"}},{"id":"dfa29ba58f4b3949a074edb1e465d30d","title":"Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2006,"evidenceTier":"phase_1_2","doi":"10.1186/cc4845","pubmedId":"16542484","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"07e70e2e2763cd412b40bb92d57f3728","title":"Controlled trial of vasopressin and balloon tamponade in bleeding esophageal varices.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":1984,"evidenceTier":"phase_1_2","doi":"10.1002/hep.1840040515","pubmedId":"6383998","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"0db444cb714014e8c71a4af42af5789c","title":"Reduction of norepinephrine versus vasopressin in the stabilization phase of septic shock: RENOVA clinical trial.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2025,"evidenceTier":"phase_1_2","doi":"10.1016/j.medine.2025.502147","pubmedId":"39890531","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"b509b33c15ffe6243a43ffe1b59a32cd","title":"Intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage: a prospective, controlled clinical trial.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":1975,"evidenceTier":"phase_1_2","doi":null,"pubmedId":"803910","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"3eee715da45f12fa32a4359c9e0ef586","title":"Vasopressin versus norepinephrine infusion in patients with septic shock.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2008,"evidenceTier":"phase_1_2","doi":"10.1056/nejmoa067373","pubmedId":"18305265","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"efbf7e77fcde25df28a4ff6d9d37adf5","title":"Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2016,"evidenceTier":"phase_1_2","doi":"10.1001/jama.2016.10485","pubmedId":"27483065","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"750e149391a546a1bda2292fccb74c12","title":"Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2017,"evidenceTier":"phase_1_2","doi":"10.1097/aln.0000000000001434","pubmedId":"27841822","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"9c4c7b6190d13fec0c77b95bdc9a894f","title":"A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2003,"evidenceTier":"phase_1_2","doi":"10.1016/s0003-4975(02)04408-9","pubmedId":"12645718","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"aedca690c591cf283e8d5b8c0d269367","title":"Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients: The VANCS II Randomized Clinical Trial.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2019,"evidenceTier":"phase_1_2","doi":"10.1097/ccm.0000000000004023","pubmedId":"31609774","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"a4f946599f66f1f621e1898a8f1ae9d0","title":"Safety and Efficacy of Vasopressin After Fontan Completion: A Randomized Pilot Study.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2019,"evidenceTier":"phase_1_2","doi":"10.1016/j.athoracsur.2019.06.053","pubmedId":"31400337","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"13f7cc3d7d8a06be864ef563b99e05fa","title":"Pilot safety study of low-dose vasopressin in non-septic critically ill children.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2009,"evidenceTier":"phase_1_2","doi":"10.1007/s00134-008-1392-1","pubmedId":"19132338","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"b4ec1a37e16a679dc96c7df06ca5b763","title":"Dilute versus concentrated vasopressin administration during laparoscopic myomectomy: a randomised controlled trial.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2017,"evidenceTier":"phase_1_2","doi":"10.1111/1471-0528.14179","pubmedId":"27362908","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"1d3ad17ac8c78262cf1778e51c4dd052","title":"A randomized comparison of vasopressin and tourniquet as hemostatic agents during myomectomy.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":1996,"evidenceTier":"phase_1_2","doi":"10.1016/0029-7844(96)00071-3","pubmedId":"8649682","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"7649005da9c75dcc3524f6d39c4ebfe6","title":"Vasopressin does not raise cardiac enzymes following cardiac surgery: a randomized double-blind clinical trial.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2015,"evidenceTier":"phase_1_2","doi":"10.1053/j.jvca.2014.07.007","pubmedId":"25440643","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"483700eb0a1c38960b50b6cad79662d7","title":"THE EFFICACY AND SAFETY OF VASOPRESSORS FOR SEPTIC SHOCK PATIENTS: A SYSTEMIC REVIEW AND NETWORK META-ANALYSIS.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2023,"evidenceTier":"observational","doi":"10.1097/shk.0000000000002193","pubmedId":"37548686","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"6567931721af466a767c742d741124bc","title":"Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2010,"evidenceTier":"phase_1_2","doi":"10.1007/s00134-009-1630-1","pubmedId":"19756505","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"983c86fa413b447cc5db88356e795ec7","title":"Comparison of intramyometrial vasopressin plus rectal misoprostol with intramyometrial vasopressin alone to decrease blood loss during laparoscopic myomectomy: Randomized clinical trial.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2018,"evidenceTier":"phase_1_2","doi":"10.1016/j.ejogrb.2018.07.006","pubmedId":"30056355","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"ffcae151c3b7ece1aa3f1f64ca1f4784","title":"Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2009,"evidenceTier":"phase_1_2","doi":"10.1164/rccm.200902-0221oc","pubmedId":"19608718","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"19a68dd008b2e767d5e97002386206c6","title":"Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2024,"evidenceTier":"observational","doi":"10.1186/s13054-024-05212-7","pubmedId":"39736782","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"99134629a26c6994f8aa58c17209c32c","title":"Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2006,"evidenceTier":"phase_1_2","doi":"10.1007/s00134-006-0378-0","pubmedId":"17019548","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"b0320bdbdaf26c2ac7e29d7bd56239a4","title":"Intra-arterial vasopressin in the human forearm: pharmacodynamics and the role of nitric oxide.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2003,"evidenceTier":"phase_1_2","doi":"10.1016/s0009-9236(03)00065-1","pubmedId":"12844130","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"2dc33d687ee9740e935f7b97d613cca0","title":"Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2015,"evidenceTier":"observational","doi":"10.1371/journal.pone.0129305","pubmedId":"26237037","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"f535e87dfe3e51cd2d61a35250538cac","title":"Vasopressin versus epinephrine for inhospital cardiac arrest: a randomised controlled trial.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2001,"evidenceTier":"phase_1_2","doi":"10.1016/s0140-6736(01)05328-4","pubmedId":"11463411","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"349ba1474e7688736ac98f0accc9ef3e","title":"Vasopressin in Cardiac Surgery: A Meta-analysis of Randomized Controlled Trials.","updatedAt":"2026-09-10T00:43:59.838Z","publicationYear":2018,"evidenceTier":"observational","doi":"10.1053/j.jvca.2018.04.006","pubmedId":"29748077","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"8747ed8824057cbe7cecc0f915024023","title":"Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2015,"evidenceTier":"phase_3","doi":"10.1007/s00198-015-3129-7","pubmedId":"26092062","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"cc788a9eb6991a6d451f112bb27cbd36","title":"Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2014,"evidenceTier":"phase_1_2","doi":"10.1210/jc.2013-4440","pubmedId":"24517156","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"d49bc556af9f7b0da981ac280a72bad8","title":"FRAX and the effect of teriparatide on vertebral and non-vertebral fracture.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2015,"evidenceTier":"phase_1_2","doi":"10.1007/s00198-015-3173-3","pubmedId":"26092063","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"ca7c29b7d152ad252c260ed5e93a4f79","title":"Safety and effectiveness of daily teriparatide in a prospective observational study in patients with osteoporosis at high risk of fracture in Japan: final report.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2016,"evidenceTier":"observational","doi":"10.2147/cia.s107285","pubmedId":"27462147","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"cc3f4d17b314eb8337bfc4d67ce632d0","title":"Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2017,"evidenceTier":"phase_1_2","doi":"10.1016/j.bone.2016.11.009","pubmedId":"27840301","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"cf1356e1d6c8ecc880d5790251a35b7b","title":"Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2005,"evidenceTier":"phase_1_2","doi":"10.1210/jc.2004-0826","pubmedId":"15613428","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"83c837ae9164d7c08f0aabacdce16bb4","title":"Teriparatide (forteo) for osteoporsis.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2003,"evidenceTier":"phase_1_2","doi":null,"pubmedId":"12571538","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"842ac646c2c657da37e65196d8d5a70f","title":"Teriparatide and pelvic fracture healing: a phase 2 randomized controlled trial.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2022,"evidenceTier":"phase_1_2","doi":"10.1007/s00198-021-06065-4","pubmedId":"34383100","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"ab0369c64072c4d0d5703e9fd3265a19","title":"Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2020,"evidenceTier":"phase_1_2","doi":"10.1200/jco.19.02192","pubmedId":"32614699","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"24022a031bf625672a9fb9bde1daba02","title":"Teriparatide treatment in severe osteoporosis - a controlled 10-year follow-up study.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2022,"evidenceTier":"phase_1_2","doi":"10.1186/s12891-022-05987-2","pubmedId":"36424580","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"aaeabc7b99b05dfbc4bd011c8585aca8","title":"PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2025,"evidenceTier":"observational","doi":"10.1007/s00198-025-07440-1","pubmedId":"40047881","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"a9e05d6fefb39ed1ce4144c230516ea9","title":"Efficacy and safety of teriparatide vs. bisphosphonates and denosumab vs. bisphosphonates in osteoporosis not previously treated with bisphosphonates: a systematic review and meta-analysis of randomized controlled trials.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2024,"evidenceTier":"observational","doi":"10.1007/s11657-024-01447-7","pubmedId":"39312040","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"f0e55845128d138e86edf8f2e0edb10b","title":"Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2020,"evidenceTier":"observational","doi":"10.3310/hta24290","pubmedId":"32588816","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"0433039100c6415f6084e97572dc7831","title":"Relative bioavailability between two teriparatide formulations in healthy volunteers.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2016,"evidenceTier":"phase_1_2","doi":"10.5414/cp202562","pubmedId":"27007999","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"508f3354e364bc1d141cb022bf03440f","title":"Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2012,"evidenceTier":"phase_1_2","doi":"10.1016/j.bone.2011.10.018","pubmedId":"22036910","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"fba453eb1f3d30381fd50af946154c76","title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2013,"evidenceTier":"phase_1_2","doi":"10.1016/s0140-6736(13)60856-9","pubmedId":"23683600","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"6ff99b045b2b29e9927d44f3b57976c1","title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2018,"evidenceTier":"phase_1_2","doi":"10.1016/s0140-6736(17)32137-2","pubmedId":"29129436","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"0e894360d9a41b6575bf754a5478ed2d","title":"Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use.","updatedAt":"2026-09-10T00:43:54.228Z","publicationYear":2019,"evidenceTier":"observational","doi":"10.1210/jc.2019-00924","pubmedId":"31265071","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}}],"regulatory":[{"id":"331d42a71868a287dea20e01764c6f90","jurisdiction":"Canada (Health Canada — Vasopressin Injection USP DIN 02139502)","status":"approved","updatedAt":"2026-09-10T00:43:59.848Z","sourceTitle":"Health Canada — Importation of US-Authorized Vasopressin Injection during Canadian shortage","sourceUrl":"https://recalls-rappels.canada.ca/en/alert-recall/importation-us-authorized-vasopressin-injection-usp-20-unitsml-iv-infusion-due-current","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"6387c812f96829dd6384d5aa5a8dadb2","jurisdiction":"United States (FDA — VASOSTRICT)","status":"approved","updatedAt":"2026-09-10T00:43:59.848Z","sourceTitle":"FDA Drugs@FDA — VASOSTRICT NDA 204485","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204485","peptide":{"slug":"vasopressin","commonName":"Vasopressin"}},{"id":"3c3257e222992d89dbb012de9a851a5f","jurisdiction":"United States (FDA — BONSITY)","status":"approved","updatedAt":"2026-09-10T00:43:54.235Z","sourceTitle":"FDA Drugs@FDA — BONSITY NDA 211939","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211939","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"9404fec00ef81a2efeb817eafc3979ce","jurisdiction":"United States (FDA — FORTEO)","status":"approved","updatedAt":"2026-09-10T00:43:54.235Z","sourceTitle":"FDA Drugs@FDA — FORTEO NDA 021318","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021318","peptide":{"slug":"teriparatide","commonName":"Teriparatide"}},{"id":"b4e4c99014bef02626f5c0f6f29fb9f4","jurisdiction":"United States (FDA — OXYTOCIN injection)","status":"approved","updatedAt":"2026-09-10T00:30:06.482Z","sourceTitle":"FDA Drugs@FDA — OXYTOCIN NDA 018248","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018248","peptide":{"slug":"oxytocin","commonName":"Oxytocin"}},{"id":"3e90e231b2e168e1f7c4e3e6f3520a1d","jurisdiction":"United States (FDA — PITOCIN)","status":"approved","updatedAt":"2026-09-10T00:30:06.482Z","sourceTitle":"FDA Drugs@FDA — PITOCIN NDA 018261","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018261","peptide":{"slug":"oxytocin","commonName":"Oxytocin"}},{"id":"386785029bae69e46b1e9cb6c640dce4","jurisdiction":"United States (FDA — MYCAPSSA)","status":"approved","updatedAt":"2026-09-09T22:55:49.827Z","sourceTitle":"FDA Drugs@FDA — MYCAPSSA NDA 208232","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208232","peptide":{"slug":"octreotide","commonName":"Octreotide"}},{"id":"0171842049517b41f7b7f0c59403684b","jurisdiction":"United States (FDA — SANDOSTATIN LAR DEPOT)","status":"approved","updatedAt":"2026-09-09T22:55:49.827Z","sourceTitle":"FDA Drugs@FDA — SANDOSTATIN LAR DEPOT NDA 021008","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021008","peptide":{"slug":"octreotide","commonName":"Octreotide"}},{"id":"b91f3ba0983591c6f3558a6dc418dbd9","jurisdiction":"United States (FDA — LUPRON DEPOT-PED)","status":"approved","updatedAt":"2026-09-09T22:55:41.464Z","sourceTitle":"FDA Drugs@FDA — LUPRON DEPOT-PED NDA 020263","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020263","peptide":{"slug":"leuprolide","commonName":"Leuprolide"}},{"id":"1082cc6a3edec1ea92683ce594c809eb","jurisdiction":"United States (FDA — LUPRON DEPOT)","status":"approved","updatedAt":"2026-09-09T22:55:41.464Z","sourceTitle":"FDA Drugs@FDA — LUPRON DEPOT NDA 019943","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019943","peptide":{"slug":"leuprolide","commonName":"Leuprolide"}},{"id":"eb37ac0c326bee2035db69311664e680","jurisdiction":"United States (FDA — lanreotide acetate)","status":"approved","updatedAt":"2026-09-09T22:31:57.556Z","sourceTitle":"FDA Drugs@FDA — Lanreotide acetate NDA 215395","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215395","peptide":{"slug":"lanreotide","commonName":"Lanreotide"}},{"id":"9e141d1a3554bd38d1fce14756971005","jurisdiction":"United States (FDA — SOMATULINE DEPOT)","status":"approved","updatedAt":"2026-09-09T22:31:57.556Z","sourceTitle":"FDA Drugs@FDA — SOMATULINE DEPOT NDA 022074","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022074","peptide":{"slug":"lanreotide","commonName":"Lanreotide"}},{"id":"5858665934ab404372095c12daa38f03","jurisdiction":"United States (FDA — DESMODA)","status":"approved","updatedAt":"2026-09-09T22:30:23.423Z","sourceTitle":"FDA Drugs@FDA — DESMODA NDA 219873","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219873","peptide":{"slug":"desmopressin","commonName":"Desmopressin"}},{"id":"e32e046c795bfef328383ebd43917f83","jurisdiction":"United States (FDA — DDAVP)","status":"approved","updatedAt":"2026-09-09T22:30:23.423Z","sourceTitle":"FDA Drugs@FDA — DDAVP NDA 019955","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019955","peptide":{"slug":"desmopressin","commonName":"Desmopressin"}},{"id":"ebfc7fd02f57e48b7f051cc1d5f03cf3","jurisdiction":"Canada (Health Canada)","status":"approved","updatedAt":"2026-09-09T22:30:01.241Z","sourceTitle":"Health Canada Product Monograph — DURATOCIN (carbetocin injection)","sourceUrl":"https://health-products.canada.ca/dpd-bdpp/index-eng.jsp","peptide":{"slug":"carbetocin","commonName":"Carbetocin"}},{"id":"481148ef5e5f0ae3fd23609ad64c8c93","jurisdiction":"Australia (TGA)","status":"approved","updatedAt":"2026-09-09T22:30:01.241Z","sourceTitle":"TGA ARTG — DURATOCIN carbetocin 100 microgram/mL injection vial","sourceUrl":"https://www.tga.gov.au/resources/artg/88468","peptide":{"slug":"carbetocin","commonName":"Carbetocin"}},{"id":"046d9fa9b6be4f5cf3bbc2752fdaca90","jurisdiction":"United States (FDA)","status":"approved","updatedAt":"2026-09-09T22:07:38.911Z","sourceTitle":"FDA Drugs@FDA NDA 020873 and ANGIOMAX Prescribing Information","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020873","peptide":{"slug":"bivalirudin","commonName":"Bivalirudin"}},{"id":"97dde1634f6dfc1bc24accdea40b1fd3","jurisdiction":"European Union (EMA)","status":"not_approved","updatedAt":"2026-09-09T22:07:38.911Z","sourceTitle":"EMA EPAR — Angiox: withdrawn marketing authorisation","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/angiox","peptide":{"slug":"bivalirudin","commonName":"Bivalirudin"}},{"id":"7594a78f777ff22286be3bbb0e0454cd","jurisdiction":"European Union (EMA)","status":"approved","updatedAt":"2026-09-09T20:35:44.336Z","sourceTitle":"EMA EPAR — Eladynos (EMEA/H/C/005928)","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/EPAR/eladynos","peptide":{"slug":"abaloparatide","commonName":"Abaloparatide"}},{"id":"a5cba6144bf989ed32e5ebc79a2d057b","jurisdiction":"United States (FDA)","status":"approved","updatedAt":"2026-09-09T20:35:44.336Z","sourceTitle":"FDA Drugs@FDA NDA 208743 and TYMLOS Prescribing Information, revised August 2026","sourceUrl":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/208743s018lbl.pdf","peptide":{"slug":"abaloparatide","commonName":"Abaloparatide"}},{"id":"c98314ad90be970cb149c87d119bb706","jurisdiction":"United States","status":"not_approved","updatedAt":"2026-09-09T19:33:05.147Z","sourceTitle":"FDA Drugs@FDA / official FDA record","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm","peptide":{"slug":"ghrp-2","commonName":"GHRP-2"}},{"id":"e36f0d7f0b9899a574a9cb3ee965f966","jurisdiction":"European Union","status":"not_approved","updatedAt":"2026-09-09T19:33:05.147Z","sourceTitle":"EMA orphan designation EU/3/21/2430","sourceUrl":"https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-21-2430","peptide":{"slug":"elamipretide","commonName":"Elamipretide"}},{"id":"58cc959cfd27bd908b738944b9eb13cd","jurisdiction":"European Union","status":"not_approved","updatedAt":"2026-09-09T19:33:05.147Z","sourceTitle":"EMA medicines portal","sourceUrl":"https://www.ema.europa.eu/en/medicines","peptide":{"slug":"ghrp-2","commonName":"GHRP-2"}},{"id":"af5285609d264b431eafecedea2bab31","jurisdiction":"European Union","status":"not_approved","updatedAt":"2026-09-09T19:33:05.147Z","sourceTitle":"EMA medicines portal","sourceUrl":"https://www.ema.europa.eu/en/medicines","peptide":{"slug":"hexarelin","commonName":"Hexarelin"}},{"id":"39366d723412bb5c6a4b2dec43c6a3b4","jurisdiction":"European Union","status":"not_approved","updatedAt":"2026-09-09T19:33:05.147Z","sourceTitle":"EMA medicines portal","sourceUrl":"https://www.ema.europa.eu/en/medicines","peptide":{"slug":"melanotan-ii","commonName":"Melanotan II"}}],"corrections":[]}